TipRanks
Scribe Therapeutics Inc. (SCTX)
NASDAQ:SCTX
US Market
SCTX
Scribe Therapeutics Inc.
RESEARCH TOOLSreports

Scribe Therapeutics Inc. (SCTX) Stock Forecast & Price Target

41 Followers
See the Price Targets and Ratings of:

SCTX Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Scribe
Therapeutics Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SCTX Stock 12 Month Forecast

Average Price Target

$51.75
▲(81.96% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Scribe Therapeutics Inc. in the last 3 months. The average price target is $51.75 with a high forecast of $60.00 and a low forecast of $37.00. The average price target represents a 81.96% change from the last price of $28.44.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","61":"$61","27.25":"$27.3","38.5":"$38.5","49.75":"$49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,27.25,38.5,49.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.175,20.46923076923077,23.76346153846154,27.05769230769231,30.35192307692308,33.64615384615385,36.940384615384616,40.23461538461539,43.52884615384616,46.823076923076925,50.11730769230769,53.41153846153847,56.705769230769235,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.175,19.834615384615386,22.49423076923077,25.153846153846153,27.81346153846154,30.473076923076924,33.13269230769231,35.792307692307695,38.45192307692308,41.111538461538466,43.77115384615385,46.430769230769236,49.09038461538462,{"y":51.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.175,18.7,20.225,21.75,23.275,24.8,26.325,27.85,29.375,30.9,32.425,33.95,35.474999999999994,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.65,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.48,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.175,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$60.00Average Price Target$51.75Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SCTX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$60
Buy
110.97%
Upside
Reiterated
09/03/26
Kapoor Reiterates Buy on Scribe, Maintaining $60 Price Target Ahead of Key STX-1150 Clinical Milestones
Wells Fargo Analyst forecast on SCTX
Yanan Zhu
Wells Fargo
Wells Fargo
$60
Buy
110.97%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top NA Picks
Leerink Partners Analyst forecast on SCTX
David Risinger
Leerink Partners
Leerink Partners
$37
Buy
30.10%
Upside
Initiated
08/18/26
Scribe Therapeutics initiated with an Outperform at LeerinkScribe Therapeutics initiated with an Outperform at Leerink
Guggenheim Analyst forecast on SCTX
Debjit Chattopadhyay
Guggenheim
Guggenheim
$50
Buy
75.81%
Upside
Initiated
08/18/26
Scribe Therapeutics initiated with a Buy at GuggenheimScribe Therapeutics initiated with a Buy at Guggenheim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SCTX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$60
Buy
110.97%
Upside
Reiterated
09/03/26
Kapoor Reiterates Buy on Scribe, Maintaining $60 Price Target Ahead of Key STX-1150 Clinical Milestones
Wells Fargo Analyst forecast on SCTX
Yanan Zhu
Wells Fargo
Wells Fargo
$60
Buy
110.97%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top NA Picks
Leerink Partners Analyst forecast on SCTX
David Risinger
Leerink Partners
Leerink Partners
$37
Buy
30.10%
Upside
Initiated
08/18/26
Scribe Therapeutics initiated with an Outperform at LeerinkScribe Therapeutics initiated with an Outperform at Leerink
Guggenheim Analyst forecast on SCTX
Debjit Chattopadhyay
Guggenheim
Guggenheim
$50
Buy
75.81%
Upside
Initiated
08/18/26
Scribe Therapeutics initiated with a Buy at GuggenheimScribe Therapeutics initiated with a Buy at Guggenheim
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Scribe Therapeutics Inc.

3 Months
Mitchell KapoorH.C. Wainwright
Success Rate
0/2 ratings generated profit
0%
Average Return
-37.25%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -37.25% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
0/2 ratings generated profit
0%
Average Return
-37.25%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.25% per trade.
2 Years
Mitchell KapoorH.C. Wainwright
Success Rate
0/2 ratings generated profit
0%
Average Return
-37.25%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -37.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SCTX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
4
5
5
Buy
0
0
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
5
6
6
In the current month, SCTX has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SCTX average Analyst price target in the past 3 months is 51.75.
Each month's total comprises the sum of three months' worth of ratings.

SCTX Financial Forecast

SCTX Earnings Forecast

Next quarter’s earnings estimate for SCTX is -$3.62 with a range of -$6.20 to -$0.74. The previous quarter’s EPS was -$2.62. SCTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year SCTX has its overall industry.
Next quarter’s earnings estimate for SCTX is -$3.62 with a range of -$6.20 to -$0.74. The previous quarter’s EPS was -$2.62. SCTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year SCTX has its overall industry.

SCTX Sales Forecast

Next quarter’s sales forecast for SCTX is $3.11M with a range of $0.00 to $7.95M. The previous quarter’s sales results were $1.92M. SCTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year SCTX has its overall industry.
Next quarter’s sales forecast for SCTX is $3.11M with a range of $0.00 to $7.95M. The previous quarter’s sales results were $1.92M. SCTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year SCTX has its overall industry.

SCTX Stock Forecast FAQ

What is SCTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Scribe Therapeutics Inc.’s 12-month average price target is 51.75.
    What is SCTX’s upside potential, based on the analysts’ average price target?
    Scribe Therapeutics Inc. has 81.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SCTX a Buy, Sell or Hold?
          Scribe Therapeutics Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Scribe Therapeutics Inc.’s price target?
            The average price target for Scribe Therapeutics Inc. is 51.75. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $37.00. The average price target represents 81.96% Increase from the current price of $28.44.
              What do analysts say about Scribe Therapeutics Inc.?
              Scribe Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of SCTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.